Search

Author/Creator Franchimont, Denis

11. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance. Issue 4 (April 2019)

Authors:
Liefferinckx, Claire; Minsart, Charlotte; Cremer, Anneline; Amininejad, Leila; Tafciu, Vjola; Quertinmont, Eric; Tops, Sophie; Devière, Jacques; Gils, Ann; van Gossum, André; Franchimont, Denis
Journal:
European journal of gastroenterology & hepatology
Issue:
Volume 31:Issue 4(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

12. Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response. Issue 2 (28th February 2021)

Authors:
Outtier, An; Wauters, Lucas; Rahier, Jean‐Francois; Bossuyt, Peter; Colard, Arnaud; Franchimont, Denis; Lambrecht, Guy; Macken, Elisabeth; Van Moerkercke, Wouter; Baert, Filip; Humblet, Evelien; Van Hootegem, Philippe; Gils, Ann; Ferrante, Marc; Vermeire, Séverine
Journal:
GastroHep
Issue:
Volume 3:Issue 2(2021)
Page Start:
63
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

13. Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy. Issue 1 (15th May 2020)

Authors:
Kopylov, Uri; Hanzel, Jurij; Liefferinckx, Claire; De Marco, Davide; Imperatore, Nicola; Plevris, Nikolas; Baston‐Rey, Iria; Harris, Richard J.; Truyens, Marie; Domislovic, Viktor; Vavricka, Stephan; Biemans, Vince; Myers, Sally; Sebastian, Shaji; Ben‐Horin, Shomron; González Lama, Yago; Gilletta...
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 52:Issue 1(2020)
Page Start:
135
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

14. Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. Issue 3 (1st April 2018)

Authors:
De Vos, Martine; Dhooghe, Barbara; Vermeire, Severine; Louis, Edouard; Mana, Fazia; Elewaut, Ann; Bossuyt, Peter; Baert, Filip; Reenaers, Catherine; Van Gossum, Marc; Macken, Elisabeth; Ferrante, Marc; Hindryckx, Pieter; Dewit, Olivier; Holvoet, Tom; Franchimont, Denis
Journal:
United European Gastroenterology journal
Issue:
Volume 6:Issue 3(2018)
Page Start:
439
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

15. Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. Issue 3 (April 2018)

Authors:
De Vos, Martine; Dhooghe, Barbara; Vermeire, Severine; Louis, Edouard; Mana, Fazia; Elewaut, Ann; Bossuyt, Peter; Baert, Filip; Reenaers, Catherine; Van Gossum, Marc; Macken, Elisabeth; Ferrante, Marc; Hindryckx, Pieter; Dewit, Olivier; Holvoet, Tom; Franchimont, Denis
Journal:
United European Gastroenterology journal
Issue:
Volume 6:Issue 3(2018)
Page Start:
439
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

16. Genome-Wide Copy Number Variation Scan Identifies Complement Component C4 as Novel Susceptibility Gene for Crohn's Disease. Issue 3 (March 2016)

Authors:
Cleynen, Isabelle; Konings, Peter; Robberecht, Caroline; Laukens, Debby; Amininejad, Leila; Théâtre, Emilie; Machiels, Kathleen; Arijs, Ingrid; Rutgeerts, Paul; Louis, Edouard; Franchimont, Denis; De Vos, Martine; Van Steen, Kristel; Georges, Michel; Moreau, Yves; Vermeesch, Joris; Vermeire, Séve...
Journal:
Inflammatory bowel diseases
Issue:
Volume 22:Issue 3(2016:Mar.)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

19. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Issue 10080 (29th April 2017)

Authors:
Feagan, Brian G; Sandborn, William J; D'Haens, Geert; Panés, Julián; Kaser, Arthur; Ferrante, Marc; Louis, Edouard; Franchimont, Denis; Dewit, Olivier; Seidler, Ursula; Kim, Kyung-Jo; Neurath, Markus F; Schreiber, Stefan; Scholl, Paul; Pamulapati, Chandrasena; Lalovic, Bojan; Visvanathan, Sudha; ...
Journal:
Lancet
Issue:
Volume 389:Issue 10080(2017)
Page Start:
1699
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

20. Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance. Issue 8 (11th May 2017)

Authors:
Liefferinckx, Claire; Minsart, Charlotte; Toubeau, Jean-François; Cremer, Anneline; Amininejad, Leila; Quertinmont, Eric; Devière, Jacques; Gils, Ann; van Gossum, André; Franchimont, Denis
Journal:
Inflammatory bowel diseases
Issue:
Volume 23:Issue 8(2017)
Page Start:
1371
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗